A kaleidoscope of selected contributions to hemostasis and thrombosis – an introduction and some editorial remarks

COVID-19 has made the year 2020 a tumultuous time and special experience to everyone in- and outside the scientific community worldwide. It can be foreseen that the pandemic will keep us busy and, simultaneously, in a kind of lockdown mode for probably another twelve months.

Publication History

Received: 16 November 2020

Accepted: 17 November 2020

Article published online:
29 December 2020

• References

• 1 Bikdeli B, Madhavan MV, Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy and follow-Up. J Am Coll Cardiol 2020; 75: 2950-2973
• 2 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033-2040
• 3 Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 2020; 40: 264-269
• 4 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
• 5 Scharf RE. Productivity of young experts in hemostasis and thrombosis before and during the SARS-CoV-2 pandemic - a special issue. Hamostaseologie 2020; 40: 255-256
• 6 Dorgalaleh A. Bleeding and bleeding risk in COVID-19. Semin Thromb Hemost 2020; 46: 815-818
• 7 Patell R, Bogue T, Bindal P. et al. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost 2020; ; Jul 21:10.1111/jth.15018
• 8 Barnes BJ, Adrover JM, Baxter-Stoltzfus A. et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 2020; ;Jun 1; 217 (06) e20200652
• 9 Scharf RE, Münzer P, Wagner DD. Basic research in COVID-19: thromboembolism, NETosis, and inflammasome. Dtsch Arztebl Int 2020 (submitted)
• 10 Holstein K, Albisetti M, Bidlingmaier C. et al. Practical guidance of the GTH haemophilia Board on the use of emicizumab in patients with Haemophilia A. Hamostaseologie 2020; 40: 561-571
• 11 Hart C, Bauersachs R, Scholz U. et al. Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE – position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis Research (GTH). Hamostaseologie 2020; 40: 572-590
• 12 Fan BE, Chang CCR, Teo CHYCR. et al. COVID-19 coagulopathy with superior mesenteric vein thrombosis complicated by an ischaemic bowel. Hamostaseologie 2020; 40: 592-593
• 13 Kelliher S, Maguire PB, Szklanna PB. et al. Pathophysiology of the venous thromboembolism risk in preeclampsia. Hamostaseologie 2020; 40: 594-604
• 14 Brackmann HH, Schramm W, Oldenburg J. et al. Origins, development, current challenges and future directions with activated prothrombin complex concentrate for the treatment of patients with congenital haemophilia with inhibitors. Hamostaseologie 2020; 40: 606-620
• 15 von Mackensen S, Douma Y, Halimeh S. Evaluation of the U.S. Adherence Questionnaires VERITAS-PRO and VERITAS-PRN for use in patients with hemophilia in the german healthcare system. Hamostaseologie 2020; 40: 621-630
• 16 von Mackensen S, Schleicher C, Heine S. et al. Health-related quality of life, treatment satisfaction and adherence outcomes of haemophilia patients living in a german rural region. Hamostaseologie 2020; 40: 631-641
• 17 Li S, Wang M, Li X. et al. Analysis of an inherited dysfibrinogenemia pedigree associated with a heterozygous mutation in the FGA Gene. Hamostaseologie 2020; 40: 642-648
• 18 Mosesson MW, DiOrio JP, Hernandez I, Hainfeld JF, Wall JS, Grieninger G. The ultrastructure of fibrinogen-420 and the fibrin-420 clot. Biophys Chem 2004; 112: 209-214
• 19 Liu S, Luo S, Yang L. et al. Phenotypic and genotypic analysis of a hereditary antithrombin deficiency pedigree due to a novel SERPINC1 mutation (p.Met281Thr). Hamostaseologie 2020; 40: 687-690
• 20 Wang Y, Zhang H, Liu S. et al. Double heterozygous mutations (Cys247Tyr and 252delAsn) cause factor XII deficiency in a Chinese family. Hamostaseologie 2020; 40: 650-654
• 21 Matzdorff A, Langer F. Factors influencing the choice between DOACs and LMWHs: A survey of German physicians on the treatment of cancer-associated venous thromboembolism. Hamostaseologie 2020; 40: 655-661
• 22 Pal R, Varma S, Ahluwalia J. et al. Antiphospholipid antibodies are not associated with clinical parameters or prognostic outcomes in patients with non-Hodgkin’s lymphoma. Hamostaseologie 2020; 40: 662-670
• 23 Bairey O, Blickstein D, Monselise Y. et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006; 76: 384-391
• 24 Gokalp C, Karadag FK, Braunisch MC. et al. In vitro closure times (PFA-100) are different between peritoneal dialysis and hemodialysis. Hamostaseologie 2020; 40: 671-678
• 25 Mahmoudpour SH, Valerio L, Douxfils J. et al. Potential drug interactions between recombinant interleukin-2 and direct oral anticoagulants: indirect evidence from in vivo animal studies. Hamostaseologie 2020; 40: 679-686
• 26 Alberio L. GTH 2021: simply online … worth experiencing. Hamostaseologie 2020; 40: 558-559